Axsome Therapeutics vs Collegium Pharmaceutical
AXSM and COLL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AXSM and COLL compare
Axsome Therapeutics is the larger company, worth 9.0 times as much as Collegium Pharmaceutical ($7.4B against $824M).
Axsome Therapeutics grew revenue faster over the last twelve months (54.2% versus 7.7% for Collegium Pharmaceutical).
Collegium Pharmaceutical keeps more of each dollar of sales as profit, with a net margin of 4.7% compared with −18.2% at Axsome Therapeutics.
Collegium Pharmaceutical scores higher on the StockData Score (9 against 8 for Axsome Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AXSM | COLL |
|---|---|---|
| Size and price | ||
| Market cap | $7.4B | $824M |
| Share price | $141.69 | $25.32 |
| Change, 1 year | 0.59% | −46.5% |
| Change, 5 years | 296% | 34.3% |
| Beta (5Y) | 0.51 | 0.47 |
| Employees | 500 | 423 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 4 (better) |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 25.3× |
| P/S | 8.6× | 1.0× (better) |
| P/B | 70.4× | 2.8× (better) |
| EV/EBITDA | – | 5.5× |
| P/FCF | – | 2.5× |
| FCF yield | −1.1% | 40.8% (better) |
| Fair value | – | $44.42 |
| Margin of safety | – | 43.0% |
| Growth | ||
| Revenue growth (TTM) | 54.2% (better) | 7.7% |
| Revenue growth, 5Y average | – | 20.3% |
| Net income growth (TTM) | – | −34.7% |
| EPS growth (TTM) | – | −37.9% |
| EPS growth, 5Y average | – | 17.9% |
| Profitability | ||
| Gross margin | 93.2% (better) | 59.0% |
| Operating margin | −17.5% | 15.2% (better) |
| Net margin | −18.2% | 4.7% (better) |
| FCF margin | −9.5% | 41.3% (better) |
| Return on equity | −176% | 13.4% (better) |
| Return on invested capital | – | 160% |
| Financial health | ||
| Debt / equity | 1.78 | – |
| Interest coverage | – | 1.6× |
| Current ratio | 1.42 (better) | 1.01 |
| Altman Z-score | 4.50 (better) | 0.81 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | −0.34% | – |
| Shareholder yield | −0.34% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 73.8% | 121% |
| Held by insiders | 15.2% | 4.3% |
| Insider net buying, 12 months | −$113M | −$4.4M (better) |
| Short interest, % of float | 7.3% | 16.7% |
Go deeper
- AXSM stock overview
- AXSM income statement
- AXSM valuation and score
- COLL stock overview
- COLL income statement
- COLL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.